Cargando…

Efficacy and safety of toripalimab combined with doxorubicin as first-line treatment for metastatic soft tissue sarcomas: an observational study

Programmed cell death protein 1 (PD-1) inhibitors have demonstrated promising activity among patients with advanced soft tissue sarcomas (STS) in phase II trials. The purpose of this study was to assess the efficacy and safety of toripalimab (a novel PD-1 inhibitor) combined with doxorubicin as firs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Zhiyong, Liu, Cuiping, Yao, Weitao, Gao, Songtao, Wang, Jiaqiang, Zhang, Peng, Ge, Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Preclinical Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448405/ https://www.ncbi.nlm.nih.gov/pubmed/34001702 http://dx.doi.org/10.1097/CAD.0000000000001088

Ejemplares similares

Safety and efficacy of combination therapy with apatinib and doxorubicin in metastatic soft tissue sarcomas: an observational study from multiple institutions
por: Tian, Zhichao, et al.
Publicado: (2019)

Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas
por: Liu, Zhiyong, et al.
Publicado: (2021)

The efficacies and biomarker investigations of antiangiogenic agents and PD-1 inhibitors for metastatic soft tissue sarcoma: A multicenter retrospective study
por: Liu, Zhiyong, et al.
Publicado: (2023)

Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study
por: Liu, Zhiyong, et al.
Publicado: (2021)

High cumulative doxorubicin dose for advanced soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)

Efficacy and safety of sintilimab plus doxorubicin in advanced soft tissue sarcoma: A single-arm, phase II trial
por: Tian, Zhichao, et al.
Publicado: (2022)

Apatinib with doxorubicin and ifosfamide as neoadjuvant therapy for high-risk soft tissue sarcomas: a retrospective cohort study
por: Tian, Zhichao, et al.
Publicado: (2021)

Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China
por: Liu, Xiaoran, et al.
Publicado: (2021)

Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin
por: Tsuchihashi, Kenji, et al.
Publicado: (2020)

Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma
por: Liu, Zhiyong, et al.
Publicado: (2022)

Toripalimab-Induced Dermatomyositis in a Patient with Metastatic Melanoma
por: Lin, Jingrong, et al.
Publicado: (2020)

Case Report: Two Cases of Soft-Tissue Sarcomas: High TMB as a Potential Predictive Biomarker for Anlotinib Combined With Toripalimab Therapy
por: Li, Yong, et al.
Publicado: (2022)

Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)
por: O’Donnell, Robert T., et al.
Publicado: (2009)

A meta-analysis of randomized controlled trials that compare standard doxorubicin with other first-line chemotherapies for advanced/metastatic soft tissue sarcomas
por: Tanaka, Kazuhiro, et al.
Publicado: (2019)

An Oral Selective Alpha-1A Adrenergic Receptor Agonist Prevents Doxorubicin Cardiotoxicity
por: Beak, Ju Youn, et al.
Publicado: (2017)

INKing the Cardiotoxicity Out of Doxorubicin
por: Guo, Zhen, et al.
Publicado: (2023)

Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer
por: Yu, Wei, et al.
Publicado: (2021)

Prospective, Multicenter Phase II Trial of Non-Pegylated Liposomal Doxorubicin Combined with Ifosfamide in First-Line Treatment of Advanced/Metastatic Soft Tissue Sarcomas
por: Buonadonna, Angela, et al.
Publicado: (2023)

Effectiveness and Safety of Toripalimab Combination Therapies for Patients With Chemo-Resistant Choriocarcinoma
por: Liu, Xiaomei, et al.
Publicado: (2022)

Severe cumulative skin toxicity during toripalimab combined with vemurafenib following toripalimab alone
por: Zhou, Hong, et al.
Publicado: (2023)

Toripalimab in advanced biliary tract cancer
por: Li, Wei, et al.
Publicado: (2022)

Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience
por: Striefler, Jana Käthe, et al.
Publicado: (2020)

Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)

Comparison between trabectedin and doxorubicin in soft-tissue sarcomas-reply letter
por: Dang, Jing-Yi, et al.
Publicado: (2022)

Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy: An observational study
por: Tian, Zhichao, et al.
Publicado: (2019)

Dynamic Augmentation of Left Ventricle and Mitral Valve Function With an Implantable Soft Robotic Device
por: Saeed, Mossab Y., et al.
Publicado: (2020)

Safety and feasibility of toripalimab plus lenvatinib with or without radiotherapy in advanced BTC
por: Wang, Yunchao, et al.
Publicado: (2023)

Retrospective analysis of metastatic behaviour of breast cancer subtypes
por: Savci-Heijink, C. Dilara, et al.
Publicado: (2015)

Influence of loading and grafting on hard‐ and soft‐tissue healing at immediately placed implants: An experimental study in minipigs
por: Parvini, Puria, et al.
Publicado: (2022)

Salinomycin increases chemosensitivity to the effects of doxorubicin in soft tissue sarcomas
por: Liffers, Sven-T, et al.
Publicado: (2013)

High tumor budding stratifies breast cancer with metastatic properties
por: Salhia, Bodour, et al.
Publicado: (2015)

Emodin induced necroptosis in the glioma cell line U251 via the TNF-α/RIP1/RIP3 pathway
por: Zhou, Jiabin, et al.
Publicado: (2019)

Circulating tumor cells in non-metastatic triple-negative breast cancer
por: Karhade, Mandar, et al.
Publicado: (2014)

Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)

Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas.The Experience of the EORTC Soft Tissue and Bone Sarcoma Group
por: Nielsen, Ole S., et al.
Publicado: (2000)

Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma
por: Jiang, Man, et al.
Publicado: (2022)

Epithelial-to-mesenchymal transition status of primary breast carcinomas and its correlation with metastatic behavior
por: Savci-Heijink, C. D., et al.
Publicado: (2019)

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
por: Seddon, Beatrice, et al.
Publicado: (2017)

Doxorubicin/Adriamycin Monotherapy or Plus Ifosfamide in First-Line Treatment for Advanced Soft Tissue Sarcoma: A Pooled Analysis of Randomized Trials
por: Wang, Bi-Cheng, et al.
Publicado: (2021)

Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure
por: Savani, Malvi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_v49g3tng8pcvor16hd4kah4lt2